Improved long-term biocompatibility of coronary stents by plasma coating process

通过等离子涂层工艺改善冠状动脉支架的长期生物相容性

基本信息

批准号：
8534805
负责人：
Meng Chen
金额：
$ 62.57万
依托单位：
NANOVA, INC.
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-08-21 至 2015-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8534805
关键词：
Acute myocardial infarction American Ammonia Animals Arterial Fatty Streak Arteries Autopsy Benign Biocompatible Materials Biological Testing Blood Clot Blood Platelets Blood coagulation Cardiac Cell Adhesion Cell Proliferation Cessation of life Clinical Coagulation Process Coronary Coronary artery Coronary heart disease Corrosion Defibrillators Deposition Development Evaluation Fibrin Generations Goals Healed Healthcare Heart Diseases Impaired wound healing Inflammatory Response Injury Knowledge Leukocytes Marketing Measurable Mechanics Medical Device Metals Myocardial Infarction Nitric Oxide Oxygen Pacemakers Patients Pharmaceutical Preparations Phase Physiologic pulse Plasma Process Recurrence Reporting Research Project Grants Resistance Risk Safety Silicon Smooth Muscle Myocytes Solutions Stainless Steel Stents Surface Technology Testing Thrombosis Tissues United States abstracting adverse outcome biomaterial compatibility cold temperature design functional group healing implantation improved in vivo innovation monomer nanoscale novel preclinical study prevent programs research and development restenosis sensor surface coating

项目摘要

DESCRIPTION (provided by applicant): Improved long-term biocompatibility of coronary stents by plasma coating process Abstract Drug-eluting stents (DES) have been widely used to treat patients of cardiac disease due to their better ability to control restenosis than bare metal stents (BMS). However, a serious adverse outcome of late stent thrombosis in patients treated with DES has been reported, which leads to fatal heart attack and death even though it occurs at low rate. Thus, for safe and effective clinical use, a coronary stent needs to have better biocompatibility on its surface that will provide sufficient thrombo-resistance in addition to inhibiting cell proliferation thereby slowing down healing of tissues around the stent. Nanova, Inc. is developing a novel coating layer of high thrombo-resistance on the surface of metallic biomaterials of which coronary stents are made. An environmentally benign technology, low temperature plasma process is used to deposit an ultra-thin (nano-scale) but continuous layer of coating, sufficient to generate desired abrasion resistance and immobilize the bioactive functional groups created in the subsequent plasma surface treatment to prevent blood clots and restenosis, but thin enough to allow for stent expansion without cracking when delivered into patients. The knowledge gained in this innovative research project will also benefit research and development for improved biocompatibility in other implantable medical devices such as pacemakers, pulse generators, cardiac defibrillators and bio-sensors.

描述（由申请人提供）：通过等离子体涂层过程提高了冠状动脉支架的长期生物相容性，因为它们比裸金属支架（BMS）更好地控制了心脏病的患者，因此已广泛用于治疗心脏病患者。然而，据报道，晚期支架血栓形成的严重不利结果已报道，接受了DES治疗的患者，即使发生率很低，也会导致致命的心脏病发作和死亡。因此，为了安全有效的临床用途，冠状动脉支架需要在其表面具有更好的生物相容性，除了抑制细胞增殖外，还可以提供足够的血栓抗性，从而减慢支架周围的组织的愈合。 Nanova，Inc。正在对制造冠状动脉支架的金属生物材料的表面上开发高血栓抗性的新型涂层。一种对环境良性技术，低温等离子体过程用于沉积超薄（纳米尺度）但连续的涂层层，足以产生所需的耐磨性，并固定在随后的血浆表面处理中产生的生物活性功能组，以防止血块和重新延伸，但可以在不裂缝的情况下进行裂缝，而无需裂缝，而无需患者裂开。该创新研究项目中获得的知识还将使研究和开发有益于改善其他可植入医疗设备（例如起搏器，脉搏发生器，心脏除颤器和生物传感器）的生物相容性。